Gilead outlays $5bn to acquire ADC specialist Tubulis
Gilead will acquire antibody-drug conjugate (ADC) developer Tubulis in a deal worth up to $5bn, continuing the big pharma company’s…
07 Apr 2026
Apnimed obtains up to $150m in funds for commercial launch of AD109
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109. The funding will…
07 Apr 2026
Neurocrine to acquire Soleno in $2.9bn transaction
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value. The transaction will expand Neurocrine’s portfolio…
06 Apr 2026
Aspect Biosystems receives funding for cellular medicine project
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and…
06 Apr 2026
MSD secures EC clearance for Keytruda combination therapy for ovarian cancer
Merck (MSD) has received the European Commission (EC) approval for Keytruda (pembrolizumab) along with paclitaxel, with or without bevacizumab, as a treatment for programmed death-ligand 1 (PD-L1)-positive ovarian cancer. The…
02 Apr 2026
Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
The US Food and Drug Administration (FDA) has approved Eli Lilly’s orforglipron pill for weight loss, ending Novo Nordisk’s first mover advantage in the US after just three months. The…
02 Apr 2026
Merck KGaA acquires JSR chromatography business
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences. This follows the company’s signing of a definitive agreement in October 2025…